What is Mysimba and what is it used for?

Mysimba is a treatment related to weight management. Hi-Doctor does not prescribe it today, but our licensed doctors can review your case and propose weight management alternatives with robust clinical evidence and EU regulatory approval.

Why does Hi-Doctor not prescribe Mysimba?

Our doctors only prescribe treatments with robust clinical evidence, an EU-approved indication and a reviewed safety profile. Mysimba is not on that list today — it may be investigational, not approved, or outside the scope of what we handle via telemedicine.

What alternatives can I consider within weight management?

Our doctors review your history and propose the most appropriate treatment among those authorised in the EU for weight management. The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; sexual health remains a €35 one-off consultation. If your case is not eligible, the applicable fee is refunded.

How would my weight management consultation work?

You fill in an online medical questionnaire (~4 min). An EU-licensed doctor reviews it and replies in less than 4 hours on average via the private chat in your account. If eligible, they issue a prescription electronic prescription valid in any EU pharmacy.

Can I get a consultation for Mysimba from Marseille?

Yes. Hi-Doctor runs 100 % online across the EU, so if you live in Marseille you can fill in the questionnaire and receive the medical review without travelling. The electronic prescription issued by the licensed doctor is valid in any EU pharmacy under Directive 2011/24/EU; outside Spain, the pharmacist dispenses the locally marketed equivalent of the same active ingredient.

Who is a candidate for a medical weight-management programme?

Adults with BMI ≥ 30, or ≥ 27 with comorbidities (hypertension, type-2 diabetes, dyslipidaemia). The doctor reviews your history, current medication and goals before proposing any treatment. It is not a cosmetic programme.

What is the private electronic prescription and why is it valid across the EU?

The private electronic prescription (Receta Médica Privada Electrónica) is issued by a licensed doctor in Spain. It is a PDF carrying every field required by EU Directive 2011/24/EU (patient, prescriber with country of registration, active ingredient, dose), which makes it legally recognised across all 27 EU member states. In Spanish pharmacies it is dispensed from the QR; outside Spain, the pharmacist dispenses the locally marketed equivalent of the same active ingredient.

How does Hi-Doctor work step by step?

1) Fill in an online medical questionnaire in about 4 minutes. 2) The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; sexual health is €35 per consultation and a skin consultation is €40. 3) An EU-licensed doctor reviews your case and, if appropriate, issues an electronic prescription. 4) Collect it at any EU pharmacy. If the review is not approved, the applicable fee is refunded in full.

How much does it cost and what does the price include?

The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; a one-off sexual-health consultation is €35 and a skin consultation — acne, rosacea, melasma, ageing skin — is €40. Each includes a licensed doctor's review and an electronic prescription if approved. If the review is not approved, the applicable fee is refunded in full. Medication is paid for separately at the pharmacy at the price it sets.

Mysimba pack shot — a prescription medicine an EU-licensed doctor can prescribe online after a Hi-Doctor consultation in Marseille.

Mysimba · Marseille

Mysimba in Marseille: what you should know.

APPROVED IN THE EUMysimba is authorised in the EU.

We don't prescribe it today, but our doctors can review your case and propose an equivalent weight management treatment with EU approval and clinical evidence.

Review my weight management case

€25/month (billed €25 every 28 days)Full refund if a review is not approved

IN PLAIN TERMS

What Mysimba is, and how to get treatment

Mysimba is a weight-management tablet that combines two long-established medicines, naltrexone and bupropion. It is authorised across the European Union and has been since 26 March 2015, so yes, a doctor in the EU can prescribe it and an EU pharmacy can dispense it. It is licensed as an addition to a reduced-calorie diet and more physical activity, for adults with a BMI of 30 or above, or a BMI of 27 to 30 with a weight-related health problem. It is not suitable for everyone: it must not be taken by people with uncontrolled high blood pressure, a history of seizures, or who are taking opioid medicines, and EU rules say it should be stopped after 16 weeks if you have not lost at least 5% of your starting weight.

Mysimba has been authorised for use in the EU since 26 March 2015, so a licensed doctor can prescribe it when it is clinically appropriate for you.

Can I get it?

Yes, if a doctor decides it is right for you. Mysimba is authorised in the EU and can be prescribed after a medical review.

What can I take instead?

Our doctors review every Weight loss option and recommend what fits your history and goals.

See all Weight loss options

What do the studies show?

Every trial behind Mysimba is listed below with its registry number, how many people took part, and whether the results are peer-reviewed or a company announcement.

Jump to the studies

Local consultation facts

Can I get Mysimba in Marseille?

Not through Hi-Doctor. Hi-Doctor does not prescribe Mysimba. People in Marseille, France, can request an online consultation for Weight loss with a licensed EU doctor, who may recommend an available option when clinically appropriate. If approved, the EU prescription arrives as a PDF for a pharmacist in France, who dispenses the locally marketed equivalent with the prescribed active ingredient.

Availability

Hi-Doctor does not prescribe Mysimba. The links below show options in Weight loss that our doctors can assess.

Country: France
Language of service: Spanish and English
Prescription turnaround: In less than 4 hours on average, only if the doctor approves
Honoured locally: PDF honoured locally for the prescribed active ingredient

How the EU prescription works where you are: In France, show the approved prescription PDF to a pharmacist. They honour it under EU cross-border rules and dispense the locally marketed equivalent with the prescribed active ingredient.

A once-daily semaglutide tablet authorised for type 2 diabetes. Any use in weight management is an individual medical decision and may be off-label.

Daily tablets

€25/month

You pay for any medication separately at the pharmacy you choose. Hi-Doctor does not sell medications.

WHAT IT COSTS

One plan, reviewed by a doctor.

Weight loss

ONGOING PLAN

€25/month

Billed €25 every 28 days · cancel anytime

28-day treatment cycle

For ongoing treatment and doctor-reviewed renewals.

Renewals reviewed by your doctor

Start consultation

Full refund if a review is not approved

WHAT'S INCLUDED

First consultation included
Renewals reviewed by your doctor
Ongoing care with your doctor
Cancel anytime

Full refund if a review is not approved

If a review is not approved, we refund that period's €25 fee and cancel the plan.

Read the refund terms

Note: The medication, if the doctor prescribes it, is paid separately at the pharmacy at the price it sets. Hi-Doctor does not sell medications.

VERIFIED EVIDENCE

Mysimba: evidence and regulatory guide.

WHAT IT IS

How it works

A tablet combining naltrexone and bupropion, which act together on the brain areas that control appetite and food reward, so hunger and cravings are reduced.

Mu-opioid receptor (blocked by naltrexone)
Dopamine transporter
Noradrenaline transporter

DEVELOPMENT STAGE

EU-authorised medicine

Trial register1 registered trials

Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.

Registered trials for Mysimba
TRIAL / NCT	POPULATION	PARTICIPANTS	STATUS	READOUT / COMPLETION
COR-INCT00532779	Adults with obesity, or overweight with high blood pressure or abnormal blood fats, without type 2 diabetes	1,742	Read out	2010-08-21

What the studies reported

Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.

Peer-reviewed

Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605. doi:10.1016/S0140-6736(10)60888-4

Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605. doi:10.1016/S0140-6736(10)60888-4
DOSE OR GROUP	MEAN WEIGHT CHANGE	WEEKS
Naltrexone 32 mg + bupropion 360 mg daily (NB32)	−6.1% body weight (−6.0 kg)	56
Placebo	−1.3% body weight (−1.3 kg)	56
Naltrexone 32 mg + bupropion 360 mg daily (NB32) — responders	48.0% lost at least 5% of body weight, versus 16.4% on placebo	56

All participants also followed a reduced-calorie diet and exercise programme, and a large proportion of people randomised did not complete the 56 weeks, which makes the average figures harder to interpret.

Sources

Last reviewed 2026-07-27

NAMED SAFETY SIGNALS

What has been reported with Mysimba.

Nausea

Reported by 31.8% of people taking Mysimba in the clinical trials, versus 6.7% on placebo. It is the most common reason people stop the medicine (6.3%).

Constipation

Reported by 18.1% of people taking Mysimba, versus 7.2% on placebo.

Vomiting

Reported by 9.9% of people taking Mysimba, versus 2.9% on placebo.

Seizures

Occurred in approximately 0.06% of trial participants taking naltrexone/bupropion (2 of 3,239), versus none of 1,515 on placebo. Mysimba must not be used by anyone with a current or past seizure disorder.

Stopping treatment because of side effects

23.8% of people taking Mysimba stopped because of an adverse reaction, versus 11.9% on placebo.

Long-term effects on the heart and circulation

The EMA completed a safety review on 28 March 2025 and concluded the benefits still outweigh the risks, while requiring an ongoing cardiovascular safety study (INFORMUS, results due 2028), an annual review of continued benefit and cardiovascular risk, and that treatment stop after one year if at least 5% weight loss is not maintained.